South Korea Daily Briefing

Chosun Ilbo's weekly market outlook flagged two macro catalysts for Korea this week: the FOMC meeting under new Fed Chair Kevin Walsh (markets pricing 25bp hold but watching for any tone shift on the terminal rate) and US-Iran ceasefire expectations ahead of the June 14 Hormuz deal signing. Both are KRW-positive — a dovish Fed keeps EM carry trades alive, and lower oil prices from Hormuz reduce Korea's energy import bill by an estimated $2-4bn/quarter at $10/bbl Brent reduction. BoK already cut in May; with KRW/USD holding near 1,370, the policy path is data-dependent through August.

Korean bank credit lending jumped ₩1.6tn in just 10 days, with top rates on margined accounts breaching 6% for the first time this cycle. This 'bidtoo' (debt-leveraged investment) pattern historically precedes higher volatility in KOSPI and KOSDAQ — when retail investors are borrowing at 6% to buy equities, they are implicitly penciling in 10%+ annual returns or near-term momentum plays. Daniel's concern: the KOSDAQ is especially vulnerable here. Shinhan's 'Super SOL' and Samsung's 'Monimo' financial super-apps are competing for the same retail credit customer, which means loan growth continues even as rates rise — watch FSC for any macro-prudential response.

Chosun Ilbo reported that OliX Pharmaceuticals (obesity drug Ollixe) faces its technology-export licensing test this summer, with GSK as a named potential partner. Korean biotech has been a consistent alpha source on the KOSDAQ — Kolon TissueGene's arthritis drug (InVossa) heads to a pivotal July FDA decision as well. The obesity drug licensing cycle (following Eli Lilly and Novo Nordisk's GLP-1 dominance) creates a secondary market for Korean peptide and RNAi platforms: any OliX-GSK deal announcement would be a KOSDAQ catalyst and validate the sector's role as a global drug discovery subcontractor, a high-margin model that trades at 30-50x forward P/E.